VIRAL BIOSAFETY OF BIOPHARMACEUTICALS
Therapeutics produced by eukaryotic cell lines could possible be contaminated with bioburden; the most dangerous for human is viral contamination. The article describes the problem of viral safety of biopharmaceuticals. The strategy of downstream process steps for the viral safety guarantee is discu...
Main Author: | D. A. Gusarov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
Series: | Разработка и регистрация лекарственных средств |
Subjects: | |
Online Access: | https://www.pharmjournal.ru/jour/article/view/226 |
Similar Items
-
Evaluation of Virus Inactivation by Formaldehyde to Enhance Biosafety of Diagnostic Electron Microscopy
by: Lars Möller, et al.
Published: (2015-02-01) -
Treatment of Rheumatoid Arthritis with Gene Therapy Applications: Biosafety and Bioethical Considerations
by: Zinovia Tsitrouli, et al.
Published: (2021-06-01) -
Biosafety Guidelines for Handling Microorganisms in the Teaching Laboratory: Development and Rationale
by: Elizabeth A.B. Emmert
Published: (2013-01-01) -
Effective inactivation of Nipah virus in serum samples for safe processing in low-containment laboratories
by: Shumpei Watanabe, et al.
Published: (2020-10-01) -
Laboratory biosafety for handling emerging viruses
by: I. Made Artika, et al.
Published: (2017-05-01)